1.
Pediatr Blood Cancer
; 64(12)2017 12.
Article
in English
| MEDLINE
| ID: mdl-28802089
Subject(s)
Chilblains/therapy , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/therapeutic use , Leukemia, Myeloid, Acute/therapy , Lupus Erythematosus, Discoid/therapy , Pancytopenia/therapy , Chilblains/etiology , Child, Preschool , Glucocorticoids/therapeutic use , Humans , Leukemia, Myeloid, Acute/complications , Lupus Erythematosus, Discoid/complications , Male , Pancytopenia/etiology , Transplantation, Homologous
2.
Scand J Rheumatol
; 44(5): 359-62, 2015.
Article
in English
| MEDLINE
| ID: mdl-25974288
ABSTRACT
OBJECTIVES: We aimed to determine how loss of response (LOR) to adalimumab (ADA) in juvenile idiopathic arthritis (JIA) may be related to anti-ADA antibodies (AAA). METHOD: AAA and ADA levels were measured in 23 consecutive patients with JIA responding significantly to treatment with ADA. RESULTS: Six out of 23 (26%) patients developed AAA and had low ADA levels. Five out of six AAA-positive patients experienced LOR. In these patients use of concomitant methotrexate (MTX) was significantly lower. CONCLUSIONS: The occurrence of AAA is a frequent event associated with LOR. Monitoring of AAA and serum ADA levels should be considered in JIA patients under ADA therapy.
